PISCATAWAY, NJ, November 7, 2005 - In a recent study entitled "Efficacy and Safety of ForsLean(R) in Increasing Lean Body Mass in Obese Subjects," participants receiving ForsLean, Sabinsa Corporation's patented Coleus forskohlii extract, showed marked improvements in lean body mass levels and reductions in body fat percentages, body weight and body mass index.
The 12-week randomized, double-blind, placebo-controlled study of 50 obese men and women revealed that subjects receiving ForsLean had a statistically significant increase in lean body mass of 1.78 percent compared to a 0.20 percent decrease in the placebo group. Additionally, the mean body fat percentage in the ForsLean group showed a statistically significant drop from 35.8 to 34.0 percent while the placebo group showed an increase from 38.8 to 39.0 percent. And after the course of the study, the mean body mass index for the ForsLean group showed statistically significant decrease from a pre-treatment value of 30.3 to 28.6 after 12 weeks, and while the placebo group decreased from 33.1 to 32.7, the change was not statistically significant.
"This study substantiates the fact that ForsLean beneficially impacts body composition in obese subjects without harmful side effects," stated Dr. Vladimir Badmaev, vice president of scientific and medical affairs, Sabinsa Corporation. "Today's consumers are increasingly searching out ways to manage their weight in a healthy fashion and ForsLean offers them a solution."
Study participants were given either 250 mg of ForsLean (standardized to 10 percent diterpene forskolin) or a placebo twice daily one half hour before meals for 12 weeks and maintained their usual levels of physical activity and normal diet patterns throughout the course of the study. No statistically significant changes were reported in lipid, renal, liver and thyroid blood biochemistry profiles.
ForsLean is an extract derived from Coleus forskohlii roots, and the only known plant source of forskolin, a natural compound that has been shown to increase lean body mass and help optimize body composition through cAMP activation. Sabinsa holds U.S. Patent #5,804,596 and European Patent #98 907 537 9 for the use of forskolin as a weight management ingredient and manufactures and supplies various extract strengths for use in a variety of supplements and products. Other international patents are pending. For more information visit www.forslean.com.
Sabinsa Corporation, founded in 1988, is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals. Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and well-being. Over the past nine years, Sabinsa has brought to market more than 30 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market. All products intended for human consumption are certified Kosher. For more information visit www.sabinsa.com or stop by booth #'s 5000/5002 at SupplySide West.
# # #